217 related articles for article (PubMed ID: 19794826)
1. Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas.
Knauer SK
J Oncol; 2009; 2009():349205. PubMed ID: 19794826
[TBL] [Abstract][Full Text] [Related]
2. An update on the pathobiological relevance of nuclear receptors for cancers of the head and neck.
Stauber RH; Wünsch D; Knauer SK; Fetz V
Histol Histopathol; 2010 Aug; 25(8):1093-104. PubMed ID: 20552557
[TBL] [Abstract][Full Text] [Related]
3. Nuclear receptors in head and neck cancer: current knowledge and perspectives.
Schweitzer A; Knauer SK; Stauber RH
Int J Cancer; 2010 Feb; 126(4):801-9. PubMed ID: 19839054
[TBL] [Abstract][Full Text] [Related]
4. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma.
Shin DM; Lee JS; Lippman SM; Lee JJ; Tu ZN; Choi G; Heyne K; Shin HJ; Ro JY; Goepfert H; Hong WK; Hittelman WN
J Natl Cancer Inst; 1996 Apr; 88(8):519-29. PubMed ID: 8606380
[TBL] [Abstract][Full Text] [Related]
5. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck.
Kleer CG; Teknos TN; Islam M; Marcus B; Lee JS; Pan Q; Merajver SD
Clin Cancer Res; 2006 Aug; 12(15):4485-90. PubMed ID: 16899593
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of chemokine receptor (CCR1, CCR3, CCR4, CCR5, CCR7 and CXCR4) expression in head and neck squamous cell carcinomas.
González-Arriagada WA; Lozano-Burgos C; Zúñiga-Moreta R; González-Díaz P; Coletta RD
J Oral Pathol Med; 2018 Sep; 47(8):755-763. PubMed ID: 29797610
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of S-phase fraction in head and neck squamous cell carcinomas and nodal negative breast carcinomas.
Fietkau R; Iro H; Tulusan AH; Dressel V; Altendorf-Hofmann A; Sauer R
Strahlenther Onkol; 1994 Jan; 170(1):13-24. PubMed ID: 8303573
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors in head-neck carcinomas].
Weber A; Tannapfel A
HNO; 2002 Jan; 50(1):35-42. PubMed ID: 11963785
[TBL] [Abstract][Full Text] [Related]
9. [Clinical analysis of 71 cases of multiple primary cancers in head and neck squamous carcinomas].
Zhou YQ; Li XM; Gao CM; Zhao QL; Li GS; Cheng JM; Shang YD
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Apr; 39(4):232-6. PubMed ID: 15283285
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas.
Zhang Z; Yang XF; Huang KQ; Ren L; Gou WF; Shen DF; Zhao S; Sun HZ; Takano Y; Zheng HC
Tumour Biol; 2015 Dec; 36(12):9487-97. PubMed ID: 26124004
[TBL] [Abstract][Full Text] [Related]
11. Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas.
Singh B; Stoffel A; Gogineni S; Poluri A; Pfister DG; Shaha AR; Pathak A; Bosl G; Cordon-Cardo C; Shah JP; Rao PH
Am J Pathol; 2002 Aug; 161(2):365-71. PubMed ID: 12163360
[TBL] [Abstract][Full Text] [Related]
12. Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.
von Mässenhausen A; Sanders C; Brägelmann J; Konantz M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Lengerke C; Perner S
Int J Cancer; 2016 Nov; 139(10):2359-69. PubMed ID: 27434411
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma.
Homann N; Nees M; Conradt C; Dietz A; Weidauer H; Maier H; Bosch FX
Clin Cancer Res; 2001 Feb; 7(2):290-6. PubMed ID: 11234882
[TBL] [Abstract][Full Text] [Related]
14. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
15. miRNA profiling of primary lung and head and neck squamous cell carcinomas: Addressing a diagnostic dilemma.
Muñoz-Largacha JA; Gower AC; Sridhar P; Deshpande A; O'Hara CJ; Yamada E; Godfrey TE; Fernando HC; Litle VR
J Thorac Cardiovasc Surg; 2017 Aug; 154(2):714-727. PubMed ID: 28495058
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas.
Shiono S; Kawamura M; Sato T; Okumura S; Nakajima J; Yoshino I; Ikeda N; Horio H; Akiyama H; Kobayashi K;
Ann Thorac Surg; 2009 Sep; 88(3):856-60. PubMed ID: 19699911
[TBL] [Abstract][Full Text] [Related]
17. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.
Spector JG; Sessions DG; Haughey BH; Chao KS; Simpson J; El Mofty S; Perez CA
Laryngoscope; 2001 Jun; 111(6):1079-87. PubMed ID: 11404625
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer.
Le QT; Giaccia AJ
Clin Cancer Res; 2003 Oct; 9(12):4287-95. PubMed ID: 14555497
[TBL] [Abstract][Full Text] [Related]
19. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
20. HPV-related carcinomas of the head and neck: morphologic features, variants, and practical considerations for the surgical pathologist.
Stevens TM; Bishop JA
Virchows Arch; 2017 Aug; 471(2):295-307. PubMed ID: 28417200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
